Novartis AG: Cardiovascular Disease Portfolio Expansion As A Critical Growth Catalyst! 

Novartis has reported a robust operational performance in its third quarter of 2024, reflecting a continuation of positive trends over the past two years. The company announced a 10% growth in sales and a 20% increase in core operating income in constant currencies. Notably, the core margin reached 40.1%. Among the highlights this quarter are several approvals and positive opinions for Novartis’s products, including Kisqali, Fabhalta, Pluvicto, and Scemblix, indicative of the firm’s focus on innovation and market expansion.